Fachliteratur Gastroenterologie: Neoplasien Oesophagus

Fr | De

Feedback | Impressum | Sitemap

Keine Artikel ausgewählt!

Warenkorb

Sie sind hier: Fachliteratursuche » Oesophagus » Neoplasie

11. September 2026

Abklärungen / Diagnostik

Therapien

Guidelines

Fortbildung

News / Journalscreening

Schrift:

Seite 1 von 1983


	Artikel 1 - 20 / 39655

	Identification of recurrence risk factors and development of personalized follow-up strategies for esophageal squamous cell carcinoma patients after neoadjuvant therapy and surgery: a retrospective cohort study. J Thorac Dis Cai Y, Wei N, Cai X, Ding J, Teng C, Chen L. PMID: 42724562 [PubMed]
	Prognostic significance of recurrent laryngeal nerve lymph node dissection in esophageal squamous cell carcinoma: a systematic review and meta-analysis. J Thorac Dis Xu S, Ni Y, Duan S, Chen Y. PMID: 42724238 [PubMed]
	Use of volumetric analysis to predict pathologic response in esophageal cancer: a single-institution cohort study. J Thorac Dis Klipsch E, Hardin S, Duckworth K, Sokevitz K, Rodgers J, Mann D, Gibney BC, Engelhardt KE, Baruah D, Bostock IC. PMID: 42724228 [PubMed]
	Impact of Dyslipidemia on Clinical Outcomes Among Cancer Patients Treated With Immune Checkpoint Inhibitors. Cancer Med Liang Y, Maeda O, Ishida S, Zennami K, Kimura T, Inoue S, Sano T, Sano Y, Naito Y, Miyata K, Shimizu D, Nishida K, Chrétien B, Kanda M, Akamatsu S, Ando Y. PMID: 42723154 [PubMed - indexed for MEDLINE]
	Artificial intelligence-based virtual iodine staining model for esophageal squamous cell carcinoma: a multicenter proof-of-concept study. Surg Endosc Zeng X, Cai L, Xiao L, Chen Z, Yin X, Yang D, Ou Y, Cheng Q, Zheng Y, Fu Z, Xiang S, Liao J, Gong X, Jiang W, Yuan X. PMID: 42722908 [PubMed - as supplied by publisher]
	Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer: Evidence, Sequencing, Patient Selection, and Clinical Decision-Making. J Gastrointest Cancer Sagawa T, Hirakawa M, Nagashima H, Fujikawa K. PMID: 42720868 [PubMed - indexed for MEDLINE]
	Comparison of in-field secondary cancer risk based on therapeutic proton dose between proton arc therapy and intensity-modulated proton therapy in lung cancer patients. J Appl Clin Med Phys Xu Y, Chen W, Wu J, Guo H, Zeng F, Zhang T, Yang F, Huang X, Zhang D, Wang X. PMID: 42717736 [PubMed - indexed for MEDLINE]
	Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases. Ann Thorac Cardiovasc Surg Suzuki T, Yajima S, Okamura A, Taniyama Y, Ohkura Y, Yagi K, Fukuda T, Ogawa R, Tsubosa Y, Shimada H. PMID: 42716804 [PubMed - indexed for MEDLINE]
	Exercise and pathologic complete response to cancer treatment: a systematic review and meta-analysis. Support Care Cancer Dias Rato N, Garcia C, Pinto D, Guedes H, Joaquim A, Viamonte S, Helguero L, Viana J, Alves A. PMID: 42714641 [PubMed - indexed for MEDLINE]
	A Combined Serum Biomarker Panel for Diagnostic and Prognostic Assessment in Esophageal Squamous Cell Carcinoma. J Vis Exp Luo J, Cao Y, Meng F, Guo C. PMID: 42714055 [PubMed - indexed for MEDLINE]
	Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer (ERSS-EGC): A study protocol for a randomized controlled trial. Chin J Cancer Res Liu M, Tian H, Huo Y, Ma J, Guo C, Xue W, Wu Q, Chen K, Li S, Li W, Liu Z, Yang W, Chen F, Sun J, Duan J, Zhang M, Pan Y, Liu Y, Chen H, Hu Z, Liu F, Wang Y, He Z, Ke Y. PMID: 42713235 [PubMed]
	Perioperative immunochemotherapy for resectable gastric or gastroesophageal junction cancer: a meta-analysis of efficacy and safety from randomized trials. Front Immunol Xu J, Li XM, Yang C, Zhang R, Lyu HL, Wang L, Xie J. PMID: 42712475 [PubMed - indexed for MEDLINE]
	Radiation dose and pathological complete response rate of neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: aÂ model-based dose-response meta-analysis. Strahlenther Onkol Jiang Y, Su T, Li Q, Feng X, Chen M, Bao W, Ye Z, Dang X, Ji Y, Yang Y. PMID: 42711378 [PubMed - as supplied by publisher]
	Metabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox. Sci Rep Tan J, Zhang H, Pan Z, Chen Y, Cui X, Wang X, Zhu G. PMID: 42711346 [PubMed - indexed for MEDLINE]
	Early recurrence patterns after neoadjuvant chemoradiotherapy and chemoimmunotherapy in esophageal squamous cell carcinoma: A multicenter study. Eur J Cardiothorac Surg Sun C, Chen C, Sun H, Liu H, Chen Q, Wang Z, Chen J, Cho WC, Li Z, Liu Z, Ma D, Ye M, Wang C, Wang Q, Leng X, Han Y, Wang Q, Lv J, Chen H, Zhao J, Yan X, Lv H, Tian Z, Wang C, Xu L, Jiang Y, Zhang Z, Zhong Q, Lin J, Mei X, Li X, Qian D, Zhu C, Guo X, Shen J. PMID: 42711264 [PubMed - as supplied by publisher]
	Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study. J Immunother Cancer Xia J, Meng X, Jiang G, Hong Y, Ji Y, Wang C, Yang X, Meng Y, Zhang W, Luo Z, Cui D, Wang J, Shan Z, Guan L, Lu Y, Yang X, Ren C, Meng X, Wang H, Shen L, Zhang Y, Kou Z, Lu T, Fan Q, Quante M, Zhao T, Li S, Wang F. PMID: 42711069 [PubMed - indexed for MEDLINE]
	First-line systemic therapy for advanced or metastatic esophageal squamous cell carcinoma: clinical implications for treatment selection after KEYNOTE-590, CheckMate 648, and RATIONALE-306. Clin J Gastroenterol Sagawa T, Nagashima H, Fujikawa K. PMID: 42709389 [PubMed - as supplied by publisher]
	Development of a biomarker-guided chemotherapy response model using combined CEA and CA19-9 profiles in esophageal cancer: A real-world pharmacotherapeutic study. Pak J Pharm Sci Can O, Sakin A. PMID: 42708782 [PubMed - indexed for MEDLINE]
	Prognostic nutritional index in evaluating the prognosis of ICIs in patients with advanced esophageal squamous carcinoma. Front Oncol Shi Q, Li M, Wang D, Yang J, Gao J. PMID: 42707258 [PubMed]
	[Adenocarcinomas of the Gastroesophageal Junction and Stomach: Current Management]. Dtsch Med Wochenschr Huber Y, Möhler M. PMID: 42705239 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 39655

Seite 1 von 1983



		Zeitfenster

Ironmedline

Das Fachportal für Eisenmangel >>

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung